Previous close | 75.03 |
Open | 75.00 |
Bid | 75.13 x 500 |
Ask | 75.18 x 500 |
Day's range | 74.59 - 75.49 |
52-week range | 60.47 - 75.81 |
Volume | |
Avg. volume | 6,384,256 |
Market cap | 233.06B |
Beta (5Y monthly) | 0.19 |
PE ratio (TTM) | 37.03 |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | 1.45 (1.93%) |
Ex-dividend date | 22 Feb 2024 |
1y target est | N/A |
Merck (MRK), Sanofi (SNY), Novartis (NVS) and AstraZeneca (AZN) announce their first-quarter results.
Fusion (FUSN) is expected to provide updates regarding the developmental program of its lead candidate, FPI-2265, for prostate cancer in the first-quarter earnings release.
AstraZeneca stock bolted higher Thursday — and is now within striking distance of a breakout — after its cancer drugs propelled a sales beat.